Page 148 - Assurance of Sterility for Sensitive Combination Products and Materials

130 Assurance of sterility for sensitive combination products and materials

York, NY USA; Toronto, Canada, 1986, p. 746.
[23] United States Pharmacopoeia (USP/NF), USP 34 General Notices and Require-
ments. 2011.
[24] U.S. Food & Drug Administration (FDA), Guidance for Industry—Container Closure
Systems for Packaging Human Drugs and Biologics—Chemistry, Manufacturing, and
Controls Documentation (http://www.fda.gov/downloads/Drugs/.../Guidances/
ucm070551.pdf). 1999: Rockville, Maryland.
[25] U.S. Food & Drug Administration (FDA), Applying Human Factors and Usability En-
gineering to Medical Devices—Guidance for Industry and Food and Drug Adminis-
tration Staff, Center for Devices and Radiological Health (CDRH), Editor. 2016.
[26] U.S. Food & Drug Administration (FDA), Draft Guidance—Human Factors Studies
and Related Clinical Study Considerations in Combination Product Design and De-
velopment, Center for Devices and Radiological Health, et al., Editors. 2016.
[27] Sterile Barrier Association, Compatibility of Materials Used for Sterile Barrier Sys-
tems with Sterilisation Processes, [cited 2017 11 July 2017]; Available from: http://
www.sterilebarrier.org/media/22919/Sterilisation-compatibility.pdf, 2010.
[28] United States Pharmacopoeia (USP/NF), Chapter <797> Pharmaceutical com-
pounding sterile preparations, in: Chapter <797>. 2016, accessed.
[29] R.J. Hernandez, S.E.M. Selke, J.D. Culter, Plastics Packaging (Properties, Processing,
Applications, and Regulations), ed. H.P.H.G. Publishers, Vol. 1, Munich, Germany;
Cincinnati, Ohio, Hanser Publishers; Hanser Gardner Publishers, 2000. 425.
[30] J.D. O’Brien, M. Sherman, Medical Device Packaging Handbook, second ed., Marcel
Dekker, 1998.
[31] U.S. Food & Drug Administration (FDA). Frequently Asked Questions About Com-
bination Products. 2016; Available from: http://www.fda.gov/CombinationProducts/
AboutCombinationProducts/ucm101496.htm.
[32] U.S. Food & Drug Administration (FDA), Early Development Considerations for In-
novative Combination Products (http://www.fda.gov/downloads/RegulatoryInfor-
mation/Guidances/ucm126054.pdf), in Office of Combination Products-Guidance
for Industry. 2011.
[33]. U.S. Food & Drug Administration (FDA), Draft-Guidance for Industry-Current
Good Manufacturing Practice Requirements for Combination Products, U.S. De-
partment of Health and Human Services, et al., Editors. 2013.
[34] U.S. Food & Drug Administration (FDA), 21 CFR—Chapter I-Food & Drug
Administration-Department of Health and Human Services- Subchapter
H—Medical Devices—Part 820 Quality System Regulation (http://www.
ecfr.gov/cgi-bin/text-idx?SID=39df3a74818e54ae1ca405f599ac630f&m-
c=true&node=pt21.8.820&rgn=div5). 2016.
[35] International Organization for Standardization, ISO 13485:2016—Medical devices—
Quality management systems—Requirements for regulatory purposes. 2016: Geneva.
[36] European Committee for Standardization, EN ISO 11607-1:2009/Amd 1:2014
Packaging for Terminally Sterilized Medical Devices—Part, Vol. 1, Requirements for
materials, sterile barrier systems and packaging systems, Brussels, Geneva, 2014.
[37] ASTM International, F2097-10 Standard guide for design and evaluation of primary
flexible packaging for medical products. 2010: West Conshohocken, PA 19428-2959,
United States.
[38] International Organization for Standardization, ISO/TS 16775 Packaging for Termi-
nally Sterilized Medical Devices - Guidance on the Application of ISO 11607-1 and
ISO 11607-2, 2014.
[39] United States Pharmacopoeia (USP/NF), USP <1207> Sterile Product Packaging—
Integrity Evaluation.
[40] L.S. Burrell, et al., Development of a dye ingress method to assess container-closure